Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Abbott International

Division of Abbott Laboratories Inc.

Latest From Abbott International

Market Intel: Increasingly Less-Invasive Diagnostic Techs To Disrupt Interventional Cardio Market

The global market for diagnostic and guided interventional cardiology products is expected to reach $4.8bn by 2021, and is driven in large part by the rising elderly population and increasing burden of cardiovascular disease (CVD). Meddevicetracker expects that intracardiac echocardiography (ICE), guide wire-based intravascular stenosis assessment (FFR) and optical coherence tomography (OCT) systems will drive overall market growth, given their high demand, which is supported by clinical evidence needed to bring cost savings and improved outcomes. Physicians' preference for using noninvasive and minimally invasive diagnostic techniques in cases where results are inconclusive is also changing the landscape of innovation. In this feature, we'll take a closer look at the overall market and its regional perspective, the competitive landscape of the three fastest-growing segments ICE, FFR and OCT, and the latest emerging technologies, as well as provide insight into what physicians think of these technologies.

Cardiology Diagnostics

Indian State FDA Calls For Probe Into ‘Exorbitant’ Stent Costs

Cardiac stent makers are under the regulatory glare in India on allegations of exorbitant charges to patients. A state-level regulator is urging the national pricing watchdog to clamp down.

Medical Device India

Indian State FDA Calls For Probe Into ‘Exorbitant’ Stent Costs

Cardiac stent makers are under the regulatory glare in India on allegations of charging exorbitantly to patients. A state level regulator has written to the national pricing watchdog to clamp down.

BioPharmaceutical Medical Device
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Therapeutic Areas
  • Alias(es)
  • Ownership
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Abbott Laboratories Inc.
  • Senior Management
  • J. Duncan McIntyre, Pres.
  • Contact Info
  • Abbott International
    ,
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register